Cryptococcosis disseminated by biological therapy, we must manage the risk

Introduction: Biological therapy for autoimmune diseases has multiple effects described, among these many secondary to the state of immunosuppression that they produce as bacterial, fungal or viral infections. Clinical case: The case of a 64-year-old female patient with proven disseminated cryptococcosis secondary to the use of tofacitinib is presented, ruling out other possible causes of immunosuppression such as the human immunodeficiency virus (HIV). The patient had been in treatment for rheumatoid arthritis which she had been diagnosed with 3 years ago. This drug is a biological agent that inhibits JAK enzymes and very few cases have been described in the literature of pulmonary and meningeal cryptococcosis in this type of patients. Conclusion: This case report is useful for other clinicians to bear in mind the possibility of this type of invasive fungal infection associated with biological therapy with a risk management approach.